Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Persistence of Hexaxim in Children
NCT01983540Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2013
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of hexaxim in diphtheria, Tetanus, pertussis and 3 more (3 arms), sponsored by Sanofi. Primary endpoint: Antibody persistence for all valences before booster doses. Started Oct 2013; status: completed.
02
Drugs
hexaxim
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT01983540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01983540.